Daniel Glenn Gibson Net Worth

The estimated Net Worth of Daniel Glenn Gibson is at least $177 millier dollars as of 4 May 2023. Daniel Gibson owns over 1,190 units of Telesis Bio Inc stock worth over $173,541 and over the last 2 years Daniel sold TBIO stock worth over $3,368.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Daniel Gibson TBIO stock SEC Form 4 insiders trading

Daniel has made over 1 trades of the Telesis Bio Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Daniel sold 1,190 units of TBIO stock worth $3,368 on 4 May 2023.

The largest trade Daniel's ever made was selling 1,190 units of Telesis Bio Inc stock on 4 May 2023 worth over $3,368. On average, Daniel trades about 397 units every 0 days since 2023. As of 4 May 2023 Daniel still owns at least 102,083 units of Telesis Bio Inc stock.

You can see the complete history of Daniel Gibson stock trades at the bottom of the page.

What's Daniel Gibson's mailing address?

Daniel's mailing address filed with the SEC is C/O TELESIS BIO INC., 10431 WATERIDGE CIRCLE, SUITE 150, SAN DIEGO, CA, 92121.

Insiders trading at Telesis Bio Inc

Over the last 6 years, insiders at Telesis Bio Inc have traded over $269,224,467 worth of Telesis Bio Inc stock and bought 73,047,057 units worth $2,753,701,666 . The most active insiders traders include Sanofi, Plc Gsk et Human Genetic Therapies, In.... On average, Telesis Bio Inc executives and independent directors trade stock every 88 days with the average trade being worth of $7,100,681. The most recent stock trade was executed by Todd Robert Nelson on 4 May 2023, trading 2,575 units of TBIO stock currently worth $7,287.

What does Telesis Bio Inc do?

sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.

Complete history of Daniel Gibson stock trades at Telesis Bio Inc

Telesis Bio Inc executives and stock owners

Telesis Bio Inc executives and other stock owners filed with the SEC include:

• Ronald Renaud,
  President, Chief Executive Officer, Director
• Richard Wooster,
  Chief Scientific Officer
• John Schroer,
  Chief Financial Officer, Treasurer
• Brian Fenton,
  Chief Business Officer
• Robert Plenge,
  Independent Director
• Robert Meyer,
  Independent Director
• George Demetri,
  Independent Director
• Daniel Lynch,
  Independent Chairman of the Board
• Daniella Beckman,
  Independent Director
• Owen Hughes,
  Independent Director
• Jean-Francois Formela,
  Independent Director
• Ann Barbier,
  Chief Medical Officer
• Frank DeRosa,
  Chief Technology Officer
• Paula Cloghessy,
  Chief Human Resource Officer
• Paul Burgess,
  Chief Operating Officer, Chief Legal Officer
• Michael Heartlein,
  Founder, Executive Vice President
• Paul M Meister,
  Director
• Everett Rand Sutherland,
  President
• Brian M. Jr. Gallagher,
  Director
• Ventures Fund Llc Mrl,
  10% owner
• Venture Fund Viii, L.P.Atla...,
  
• Plc Gsk,
  10% owner
• Human Genetic Therapies, In...,
  
• Fund Iv, L.P.Omega Fund Iv ...,
  
• James B Weissman,
  
• Michael R. Hodges,
  
• Todd Krueger,
  
• Steven J Golub,
  
• Sarah E. Hlavinka,
  
• Daniel Glenn Gibson,
  Chief Technology Officer
• Human Genetic Therapies, In...,
  
• Group Llc/Ma Baupost Group ...,
  
• Brendan Smith,
  Chief Financial Officer
• Sanofi,
  10% owner
• Ventures Gp, Llc Northpond ...,
  
• Fund Iv, Llc Broad Oak,
  10% owner
• William Snider,
  Director
• William J Kullback,
  Chief Financial Officer
• Rob Cutler,
  Chief Legal Officer
• Todd Robert Nelson,
  Chief Executive Officer
• Eric Eugene Esser,
  President & CEO
• Frank Witney,
  
• Christine A Tsingos,
  
• Annette Tumolo,
  
• Gregory J. Herrema,
  
• Jami K Nachtsheim,